Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Part of paid clinical trials in Hot Springs, Arkansas.

Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study ID
NCT00083486
Phase
PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • epoetin alfa — DRUG

Study Details

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Key Dates

First listed
May 27, 2004
Start date
Feb 29, 2004
Status verified
Apr 2011
Completion
Oct 31, 2004

Study Design

Primary purpose
TREATMENT

Locations (12)

FacilityCityStateZIPSite coordinators
Heritage Physician Group-OncologyHot SpringsArkansas71913-
Spalding Oncology ServicesGriffinGeorgia30224-
Southern Illinois HematologyCentraliaIllinois62801-
BioLab ResearchRockvilleMaryland20852-
Slocum-Dickson Medical Group, PCNew HartfordNew York13413-
NorthEast Urology ResearchConcordNorth Carolina--
Mid Ohio Oncology HematologyColumbusOhio43213-
Drexel University College of MedicinePhiladelphiaPennsylvania19102-
Caroline Cancer CenterAikenSouth Carolina29403-
Charleston Cancer CareCharlestonSouth Carolina29406-
Charleston Hematology OncologyCharlestonSouth Carolina29403-
Volunteer Research GroupKnoxvilleTennessee37920-

Find similar trials in Hot Springs, AR

Related Studies